GlassScriptPhysician profile
Loc Vo
NPI 1033615216
$6,751.23
in general payments reported to CMS, 2019-2025
39 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,307 · 2024: $2,145 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,576 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,576.23 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $830.81 | 2024-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $783.53 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Mannkind Corporation | $506.09 | 2023-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $459.75 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $445.93 | 2023-2025 | |
| Novo Nordisk INC | $443.73 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $442.12 | 2023-2025 | Synthroid, Linzess, Ubrelvy |
| Corcept Therapeutics | $302.12 | 2024-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $227.45 | 2023-2025 | Yorvipath |
| Pfizer INC. | $222.84 | 2023-2025 | |
| Exact Sciences Corporation | $197.94 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $148.12 | 2024-2025 | Xyosted |
| Kyowa Kirin, INC. | $139.42 | 2025 | |
| Lundbeck LLC | $135.92 | 2024-2025 | Rexulti |
| Intuity Medical INC | $134.34 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $125.22 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $117.57 | 2023-2025 | Lokelma, Breztri, Airsupra |
| Hologic Sales and Service, LLC | $102.08 | 2025 | Coolseal Generator |
| Novartis Pharmaceuticals Corporation | $86.93 | 2024 | |
| Xeris Pharmaceuticals, INC. | $82.90 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $73.65 | 2025 | Unithroid |
| Radius Health, INC. | $70.86 | 2025 | Tymlos, Binosto |
| Recordati_rare_diseases_inc. | $67.14 | 2025 | Isturisa |
| Acella Pharmaceuticals, LLC | $64.54 | 2024-2025 | NP Thyroid 60 |
| Intra-Sana Laboratories | $61.17 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Neurocrine Biosciences, INC. | $56.52 | 2025 | |
| Insulet Corporation | $56.20 | 2024-2025 | Omnipod |
| Madrigal Pharmaceuticals | $52.22 | 2025 | Rezdiffra |
| Dexcom, INC. | $51.16 | 2023-2024 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $42.27 | 2023-2025 | Strensiq |
| Currax Pharmaceuticals LLC | $32.62 | 2024-2025 | Contrave |
| Eisai INC. | $31.90 | 2025 | |
| Halozyme INC | $27.36 | 2023 | |
| Tandem Diabetes Care, INC. | $25.24 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $23.52 | 2023 | Tirosint, Licart |
| Verity Pharmaceuticals INC. | $20.80 | 2025 | Tlando |
| Chiesi USA, INC. | $20.72 | 2024 | Mycapssa |
| Tolmar, INC. | $19.82 | 2024 | |
| Medtronic, INC. | $18.71 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loc Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.